Twist Bioscience (TWST) Cash from Financing Activities (2017 - 2026)

Twist Bioscience has disclosed Cash from Financing Activities across 10 years of filings, most recently posting $4.1 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 29.47% year-over-year to $4.1 million; the TTM figure through Mar 2026 stood at $11.8 million (down 57.23% YoY), while the FY2025 annual figure was $28.5 million, up 314.22% from the prior year.
• Cash from Financing Activities advanced to $4.1 million in Q1 2026, from $298000.0 in the prior quarter.
• Over the last five years, Cash from Financing Activities for TWST reached as high as $271.6 million in Q1 2022 and fell as low as -$1.5 million in Q4 2023.
• The 5-year median for Cash from Financing Activities is $1.8 million (2025), against an average of $18.4 million.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities soared 18619.23% — and 2023, when it plunged 272.91%.
• A 5-year view of Cash from Financing Activities shows it stood at -$395000.0 in 2022, then sank by 272.91% to -$1.5 million in 2023, then soared by 1318.19% to $17.9 million in 2024, then sank by 98.34% to $298000.0 in 2025, then surged by 1288.59% to $4.1 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $4.1 million, $298000.0, and $5.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.